Achilles therapeutics demonstrates cnet product characterization and post-infusion tracking in a patient case study at the american association for cancer research (aacr) 2021 annual meeting

London, april 10, 2021 (globe newswire) -- achilles therapeutics plc (nasdaq: achl), a clinical-stage biopharmaceutical company developing precision t cell therapies to treat solid tumors, today presented a patient case study from the company's ongoing phase i/iia thetis trial in metastatic or recurrent melanoma at the american association for cancer research (aacr) annual meeting 2021. through a comprehensive translational research program, data from patient t-05 offer insight into the in vivo dynamics of clonal neoantigen t cells (cnet) post-dosing and the potential to develop a potency-based release assay.
ACHL Ratings Summary
ACHL Quant Ranking